CMMB Chemomab Therapeutics Ltd
Price (delayed)
$1.13
Market cap
$21.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.86
Enterprise value
$15.48M
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of
Highlights
CMMB's EPS has surged by 58% year-on-year and by 14% since the previous quarter
CMMB's net income is up by 42% year-on-year and by 3.2% since the previous quarter
CMMB's equity is down by 20% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of CMMB
Market
Valuations
Earnings
Shares outstanding
18.86M
Market cap
$21.31M
Enterprise value
$15.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$14.74M
Net income
-$13.95M
EBIT
-$13.95M
EBITDA
N/A
Free cash flow
N/A
Per share
Balance sheet
Liquidity
EPS
-$0.86
EPS diluted
-$0.86
Free cash flow per share
N/A
Book value per share
$0.72
Revenue per share
$0
TBVPS
$1.05
Total assets
$16.96M
Total liabilities
$3.43M
Debt
$324,000
Equity
$13.54M
Working capital
$12.82M
Debt to equity
0.02
Current ratio
4.98
Quick ratio
4.98
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-79.2%
Return on equity
-104.9%
Return on invested capital
-169.6%
Return on capital employed
-101.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMMB stock price
How has the Chemomab Therapeutics stock price performed over time
Intraday
8.65%
1 week
-2.59%
1 month
-32.74%
1 year
48.29%
YTD
-37.57%
QTD
3.67%
Financial performance
How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.74M
Net income
-$13.95M
Gross margin
N/A
Net margin
N/A
Chemomab Therapeutics's operating income has increased by 42% YoY and by 4.1% from the previous quarter
CMMB's net income is up by 42% year-on-year and by 3.2% since the previous quarter
Growth
What is Chemomab Therapeutics's growth rate over time
Valuation
What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
1.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS has surged by 58% year-on-year and by 14% since the previous quarter
CMMB's price to book (P/B) is 21% more than its 5-year quarterly average of 1.2 but 3.3% less than its last 4 quarters average of 1.5
CMMB's equity is down by 20% YoY and by 17% from the previous quarter
Efficiency
How efficient is Chemomab Therapeutics business performance
Chemomab Therapeutics's return on invested capital has increased by 36% YoY
The return on assets has increased by 11% year-on-year but it has declined by 3.9% since the previous quarter
CMMB's return on equity is up by 8% year-on-year but it is down by 3.1% since the previous quarter
Dividends
What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMMB.
Financial health
How did Chemomab Therapeutics financials performed over time
The total liabilities has declined by 34% year-on-year and by 25% since the previous quarter
CMMB's total assets is down by 23% year-on-year and by 19% since the previous quarter
The debt is 98% lower than the equity
CMMB's equity is down by 20% YoY and by 17% from the previous quarter
The debt is down by 17% YoY and by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.